

ADHD Prescribing Manual For Australian Healthcare Professionals

1ST EDITION 2024



DISCLAIMER

Information for Healthcare Professionals Only

The content of the ADHD Prescribing Manual for Australian Healthcare Professionals, published by the Australasian ADHD Professionals Association (AADPA), is directed solely towards qualified Australian healthcare professionals. It provides information on attention deficit hyperactivity disorder (ADHD) treatment using medications. The information is based on a combination of:

- *Evidence-based research for the authors*
- *The Australian Evidence-Based Clinical Guideline for ADHD*
- *Expertise of leading Australian healthcare professionals in the field of ADHD*

Important Considerations

- *Limited Scope: This manual is intended for use within Australia. Regulatory requirements for ADHD medications vary across states and territories and users of this manual should make themselves aware of the relevant guidelines. Further, regulatory requirements may differ in other countries. Please consult the relevant guidelines in your jurisdiction if you practice or prescribe medications outside of Australia.*
- *Individualised Care: This manual provides general information. The specific needs of each patient will vary. Healthcare professionals must exercise their clinical judgement and expertise when applying these recommendations to individual cases.*
- *Not a Substitute for Professional Advice: The information in this manual is not a replacement for professional medical advice, diagnosis, or treatment. Always exercise your clinical judgement or consult with a qualified healthcare professional before making any medical decisions or adjustments to a patient's care plan.*

Liability

The authors, editors, and the publisher, the Australasian ADHD Professionals Association (AADPA), do not accept any liability for:

- *Errors or omissions in the information presented.*
- *Any outcomes resulting from the application of the information provided.*

Copyright and Ownership

All materials contained within this ADHD Prescribing Manual are copyrighted by the Australasian ADHD Professionals Association (AADPA) © 2024. The manual's authors retain full rights to the information from their own individual contributions. This manual cannot be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law.

FOREWORD

Advancing ADHD Care Together

The prescribing of medication for ADHD has been a hot topic of discussion in Australia in recent years. Official data has highlighted significant variability in ADHD prescribing across the country and it is common to hear questions about a wide range of issues such as which medications should be used, who should receive them and at what doses.

This prescribing manual, developed by members of the Australasian ADHD Professionals Association (AADPA) aims to address these questions and concerns and provide a clear path forward, with safe and responsible models of care for healthcare professionals.

While there are clear, well established, general principles, for starting, adjusting, and stopping medications there are some specific considerations that need to be addressed when prescribing for ADHD.

This manual has been written to guide practice and bridge the gap between evidence and practice. It's designed to be a helpful companion for healthcare professionals navigating the world of ADHD medication. It aligns with the Australian Evidence-Based Clinical Practice Guideline for ADHD, the gold standard for ADHD assessment, diagnosis and treatment in this country. While the focus is on Australia much of the advice is general and will be applicable across multiple settings.

In developing the manual we followed many of the same principles that were used to develop the ADHD Guideline. We consulted widely among professionals (author list - [hyperlink/not necessary for the print version](#)) and we are grateful for the support and guidance provided by this group. We intend that the manual will be a living document and AADPA will maintain and update the content when necessary.

We hope that the question-and-answer format makes the manual more user-friendly and makes it easier to find the information you are looking for.

The first section follows a typical patient journey, addressing common questions you might encounter when starting someone on medication. There are also lived experience perspectives throughout the manual. The second section tackles more specific situations through a handy FAQ format.

It is important to note however that this manual, with its focus on medication, is just one piece of the bigger picture in ADHD treatment. Especially for those aged 5 and up, it's important to remember that a successful approach to managing ADHD includes a mix of strategies..

For people with ADHD and their parents, families and supporters, **high quality psychoeducation should form the platform from which all other support is launched.**

There are many non-medication treatment options available. These are covered in detail in the ADHD Guideline and through the AADPA factsheets. It is always important to think about other approaches such as parent training, cognitive therapy approaches, and ADHD coaching.

There are programs that can help parents understand and support their child's needs. This can not only reduce stress, but also improve family dynamics and allow those with ADHD, as well as those around them, to thrive.

Also, by working together, and collaborating with schools and workplaces, we can strive to create a more supportive environment for people living with ADHD, leading to better academic, work and overall health and wellbeing outcomes.

While there's no magic bullet for treating and supporting ADHD, helping individuals develop strategies for organisation and mental health can make a big difference. Better targeted and thorough research is also needed to better understand how ADHD presents and impacts particular groups including girls and women and first nations people, and to develop more efficient and effective models of care that better help people living with ADHD and increase our understanding of how the condition impacts individuals across the lifespan.

We sincerely hope that you find this manual helpful when working with individuals and families who are living with ADHD and that it can help us work together to advance ADHD care.

Best regards,



A handwritten signature in black ink, appearing to read 'D Coghill'.

Professor Dave Coghill

Lead Author



A handwritten signature in black ink, appearing to read 'Kate Tognarini'.

Kate Tognarini

Lead Author

Author List:

Dave Coghill, Psychiatrist, MB, ChB, MD, FRANZCP, FRCPsych, Financial Markets Foundation Chair of Developmental Mental Health, University of Melbourne; Professor of Child and Adolescent Psychiatry and Consultant Psychiatrist, Royal Melbourne Hospital, Melbourne and Orygen youth Health, Melbourne. COI: DC has received honoraria from Medice, Novartis, Servier and Takeda, royalties from Oxford University Press and Cambridge University Press, is the President and an unpaid Director of the Australian ADHD Professionals Association (AADPA) and is an unpaid Director of EUNETHYDIS.

Katarzyna (Kate) Tognarini, Pharmacist, BSc (Hons), B.Pharm, member PSA, Community Pharmacist Good Health Pharmacy Mentone Victoria, Member CADDRA COI: KT is an unpaid Casual Director of AADPA.

Roger Paterson, Psychiatrist, MB BS, FRCPsych, FRANZCP, Cert Child Adolesc Psych, Private practice, Hollywood Specialist Centre, Nedlands, Western Australia. COI: RP received sponsorship to attend educational events from Takeda, Lundbeck, Servier and Novartis. RP is an unpaid Director and Vice-President of AADPA.

Sarah Lovett, Consultant General Paediatrician, FRACP, BMedSci, MBBS Hons, Dip Med Ed, GCAD, Hunter New England Area Health - VMO Paediatrician. COI: SL is an unpaid Casual Director of AADPA.

Alison (Sally) Poulton, Paediatrician, MA MB BChir, MD (Cantab) MRCP, FRACP, Senior Lecturer in Paediatrics, Nepean Clinical School, University of Sydney. COI: AP is an unpaid Director of AADPA. AP has received honoraria from Shire/Takeda and royalties from Disruptive Publishing.

John W Kramer OAM, Specialist General Practitioner, MBBS; FRACGP, FACRRM, Adjunct Associate Professor UNSW Medicine Coffs Harbour Rural Clinical School; Chair RACGP ADHD, ASD and Neurodiversity Special Interest Group within the Faculty of Specific Interests; General Practitioner, Beach Street Family Practice, Woolgoolga, NSW. Board Chair, NSW Rural Doctors Network. Member Paediatric Network Executive Committee, ACI, NSW Health Dept. Member RACGP Rural Faculty Council. COI: JK is an unpaid Casual Director of AADPA.

Lou Brown, RN (non-practicing), ADHD Coach (non-practicing), PhD Candidate, B.Sc. (Nursing), Post Grad Cert, ACC, Curtin University, Thriving with ADHD. COI: LB is an unpaid Appointed Director of AADPA, RTP Scholarship recipient - Curtin University, income from 'ADHD in primary school: Understanding and supporting students with ADHD in the classroom', ADHD workshops, written material and speaking engagements.

Mark A. Bellgrove, Cognitive Neuroscientist, BSc (Hons), PhD, FASSA, School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne. COI: MAB is the Immediate-Past President of AADPA and a current unpaid Director.

Frank Cahill, Clinical Psychologist, B.A., Grad Dip Applied Psych, Dpsych, Monash University clinical supervisor, Epworth Sleep Centre. COI: None declared.

Lakshman Doddamani, Neurodevelopmental Paediatrician, MBBS, DNB (Paed), FRCPCH (UK), FRACP, Consultant Paediatrician; Grampians Health, Member NBPSA. COI: LD has received honoraria from Takeda.

Shelley Gray, General Practitioner, MBBS, Practice Principal The Town Medical centre, 5/179 Queen Street, Melbourne, consultant to BeyondGP. COI: None declared.

Dianne Grocott, Psychiatrist, MBBS, FRANZCP, Reflect Health Private Psychiatry Practice COI: DG has received honoraria from Shire/Takeda.

Jarret Johnston, Psychiatrist (Child, Adolescent and General), MBBS UNSW, FRANZCP, Cert Child Adol Psych, Private Practice, Contract child protection work for Department of Communities and Justice through Marathon Health. COI: None declared.

Alicia Montgomery, Developmental Paediatrician, BMed/MedSci(Hon), FRACP, MPH, AADPA, UNSW, Sydney Local Health District, Sydney Children's Hospital Network. COI: None declared.

Belinda Oddy, Psychiatrist, MBBS, B.Med Sci., FRANZCP, Cert. Consultation-Liaison Psych. Cert. Addiction Psych. Consultant Psychiatrist, Royal Brisbane and Womens' Hospital. Visiting Medical Officer, Brisbane Private Hospital. COI: None declared.

Professor Edward Ogden PSM, Addiction Medicine Specialist, MA MBBS, BMedSc, GradCertMgt, FRACGP FACHAM FFCFM(RCPA), Senior Research Fellow (Clinical Trials), Centre for Mental Health and Brain Sciences Swinburne University of Technology, Addiction Medicine Specialist, Austin Health (Hamilton Centre) Melbourne, Addiction Medicine Specialist, Goulburn Valley Alcohol and Drug Service, Shepperton. COI: None declared.

Carmel O'Toole, Specialist General Practitioner and Medical Educator, MBBS, FRACGP, GCHPE, Founding Member (with John Kramer) Specific interest Group in ADHD and Neurodiversity, RACGP, Former Examiner and Medical Educator, RACGP, Former Senior Lecturer, Monash University. Director BeyondGP Health Professional Education www.beyondgp.com.au, Specialist GP in Adult ADHD, Member AAADHDIG, Member CADDRA. COI: None declared.

Marshall Watson, Child and Adolescent and Forensic Psychiatrist, MBBS, FRANZCP, AFRACMA, Child and Adolescent and Forensic Psychiatrist Carrington Street Consulting, Adelaide SA, Child and Adolescent Forensic Psychiatrist, Forensic Child and Youth Mental Health Service Queensland health, Honorary Research Associate, Telethon Kids institute, Perth Childrens Hospital, Member NBPSA. COI: None declared.

Table of Contents



PART 1 – The Patient Journey

Foreword	01
Author list	03
Introduction	12
If ADHD has been diagnosed, when should ADHD medications be considered?	12
Who should prescribe ADHD medications?	13
What are the important issues to consider when a decision has been made to start pharmacological treatment for ADHD?	14
Understanding the pharmacokinetics and pharmacodynamics of the medications used to treat ADHD	14
Psychoeducation and consent	14
What additional assessments should be conducted prior to starting medication?	15
BOX 1: Cardiac Risk Assessment	16
Off-label prescribing	17
BOX 2: Principles when considering an off-label trial of psychotropic medication for children and adolescents	18
Medication choice	20
Which should be the first medication for ADHD?	20
Why one stimulant would be used over another?	20
What are the key differences between dexamfetamine and methylphenidate?	20
Why is it necessary to understand the pharmacokinetic and pharmacodynamic profiles of the stimulants?	21
How do you switch between different methylphenidate preparations?	21
Clinical Practice Points for extended-release methylphenidate preparations:	22
TABLE 1: Dose equivalence chart for switching between methylphenidate preparations	23
How do you switch between dexamfetamine and lisdexamfetamine?	24
Clinical Practice Points for lisdexamfetamine	24
What are the best medication choices for children aged under 5 years?	24
What are the best medication choices for children and adolescents (aged 5 to 17 years) and adults (aged 18 years and above)?	25
Do the recommendations differ for adults over the age of 65 years?	26
What are the contraindications to using stimulant medications across the lifespan?	26
Medication choices for those with coexisting mental health conditions	26
Psychosis	27
Anxiety, mood disorders, tic disorder and autism spectrum disorder	27

Medication choices for those with coexisting substance use disorder	27
When should a non-stimulant medication be considered as a first choice for children and adolescents with ADHD?	28
When should a non-stimulant medication be considered as a first choice for adults with ADHD?	28
Titration and optimising dose	29
What is meant by optimising ADHD core symptoms and what are the best approaches to optimisation?	29
TABLE 2: Interpreting core symptom outcomes using standardised DSM-based rating scales (e.g., ADHD-RS-5, SNAP-IV or Vanderbilt score).*	31
Are there situations when the approach to titration should be adjusted?	32
Titration Protocols- Stimulants	32
Should you start with a short acting or long-acting stimulant?	32
How fast should you titrate onto stimulants?	32
What are the maximum doses of the stimulants?	33
Examples of stimulant titration protocols used by the authors	34
Titration protocol - atomoxetine	34
Titration protocols - extended release guanfacine	35
Titration protocols - clonidine	36
What should I do if the first medication is not effective or tolerated?	36
If the first medication has been a stimulant and is not effective	37
If the first medication is poorly tolerated due to adverse effects	37
If the first medication has been a non-stimulant and is ineffective or not tolerated	38
If both stimulant classes have been tried at adequate doses and have either not been effective or not tolerated	38
Monitoring progress	40
How often should progress be monitored?	41
What should be included in a medication review appointment?	41
What rating scales are recommended for monitoring core ADHD symptoms?	41
Outcome measures for children and adolescents:	41
TABLE 2: Interpreting core symptom outcomes using standardised DSM-based rating scales (e.g., ADHD-RS-5, SNAP-IV or Vanderbilt score).*	43
Outcome measures for adults:	43
What are the best ways to monitor adverse effects?	43
TABLE 3: Monitoring other symptoms/adverse effects	44
The AADPA ADHDTracker App - a useful online tool for monitoring progress	45
Optimising long-term outcomes: what does the research say and why does it matter?	45

How long should you treat ADHD and how do you know when to stop medication?	46
Are there specific recommendations for stopping the different ADHD medications?	46
What approaches can help to maximise adherence to treatment?	47
How can we best engage children and young people in their treatment?	47
Should you use medication holidays?	48
What are the important things to consider before switching medications?	48
BOX 3: Questions to consider before switching medications or adding an additional medication	49
If I am going to switch medication class, what order should I proceed in?	49
How do I tell if someone is becoming tolerant to their medication and if they are, what should I do?	50
Managing adverse effects	52
What are the best practical approaches to aid in weight maintenance and growth	52
How do you monitor cardiovascular safety?	53
Other adverse effects	53
TABLE 4. Summary of recommendations updated from the European ADHD Guidelines Group review of the management of best practice in the management of adverse events during treatment with ADHD (Cortese et al 2013)(56)	55
References	58
Appendix 01: SUMMARY TABLE for ADHD medications	62
Appendix 02: Medical and psychiatric precautions or contraindications for ADHD medications Author Katarzyna (Kate) Tognarini	66
Appendix 03: ADHD Medication use in Pregnancy and Breastfeeding Author Katarzyna (Kate) Tognarini	70
Appendix 04: Medication interactions, metabolism & elimination, side effects Author Katarzyna (Kate) Tognarini	74
Appendix 05: Sample titration protocols	80
Dr Alison (Sally) Poulton - Paediatrician	80
David Coghill (child and youth psychiatrist) – titration onto methylphenidate, dexamfetamine, and lisdexamfetamine	83
Roger Paterson (child & adolescent and adult psychiatrist)	85
Roger Paterson - Medication Dose Schedule Guideline – Methylphenidate - Children	87
Roger Paterson - Medication Dose Schedule Guideline Dexamfetamine - Children	88
Roger Paterson - Medication Dose Schedule Guideline – Methylphenidate - Teens and Adults	89
Roger Paterson - Medication Dose Schedule Guideline – Dexamfetamine and Lisdexamfetamine - Teens and Adults	90

PART 2 – Frequently Asked Questions

1. When would you use the ‘further medication choices’ listed in the Guideline?	93
2. Acidifying/Alkalinizing Agents – what is the interaction between these and stimulant medications?	94
Interactions with Acidifying/Alkalinizing Agents	94
3. End of Dose Behaviour/Mood Changes – what can help?	95
4. What are the Pharmaceutical Benefits Scheme (PBS) Listings for ADHD Medications?	96
5. Which ADHD Medications contain Gluten and Lactose?	97
6. Can Lisdexamfetamine (Vyvanse) be Dissolved and Diluted and if so, what is the Stability?	98
7. How Can Pharmacists Help To Support People who are Using ADHD Medications?	99
Counselling on Specific Medication Types, Expected Effects, Side Effects, and Interactions	100
Information on Combining Medications with Caffeine, Alcohol or Cold and Flu Medications	101
8. Other Considerations (Special Populations - Comorbidities)	102
Comorbidities: How should Clinicians Approach Prescribing Stimulants to Patients with Other Conditions?	102
General comments on prescribing in the presence of other conditions from the Australian ADHD Evidence-Based Guideline Development Group:	102
Comorbidities: Does a clinician have to be wary or make any changes to practice when prescribing ADHD medications, to patients with a history of:	103
Anxiety	103
Depression	105
Tic Disorders (Tourette's Disorder)	106
Autism Spectrum Disorder (ASD)	108
Epilepsy	110
Psychosis/Schizophrenia/Drug-Induced Psychosis	112
Bipolar Disorder	115
Oppositional Defiant Disorder (ODD)	116
What are the recommendations for ADHD medications in the presence of Disordered Eating	118
Restless Legs Syndrome (RLS)	120
Skin Picking Behaviours and ADHD	122

9. Is there an association between Substance Use Disorder and ADHD and what are the recommendations?	123
10. Are there recommendations for Cannabis Use and Access to Medication?	125
11. Is there an association between Gambling Disorder (GD) and ADHD and what are the recommendations for treatment?	126
12. Are there specific issues for using ADHD medications in females: in general; during pregnancy; and while breastfeeding?	127
General Issues	127
Gender-Specific Issues in Diagnosis and Prescribing for Females	127
Hormonal Influences on Cognition and Mood	127
Comorbidities and Hormonal Fluctuations	128
The Role of Iron Status	128
Managing ADHD in Times of Hormonal Fluctuations	128
Medication Use in Pregnancy and Lactation	130
13. What are the Sleep Considerations for people with ADHD?	132
Does taking Melatonin Stop the Brain from Producing Its Own Melatonin?	133
14. Are Supplements, Nutraceuticals, and Phytochemicals recommended in managing ADHD?	134
15. Driving and Roadside Tests: When it comes to driving and the use of stimulant medications for ADHD, what are the implications to consider?	137
16. Is there any data on the Long-Term Safety of Stimulant Medications?	139
17. What are the considerations for Domestic and International Travel?	141
18. Are there any considerations for the Criminal Justice System?	142
19. What are the Considerations with Sport?	143
20. What are the Career and Occupational Considerations?	144
21. Are there any recommendations for Pharmacogenetic Testing?	145
23. Are there particular issues regarding treatment of ADHD in Aboriginal and Torres Strait Islander Peoples?	146